New anti-parasitic drugs for a global veterinary market

面向全球兽医市场的新型抗寄生虫药

• 批准号: LP190101209
• 负责人: Prof Robin Gasser
• 金额: $ 53.31万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2020
• 资助国家: 澳大利亚
• 起止时间: 2020-11-13 至 2023-11-12
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP190101209
• 关键词: New; anti; parasitic; drugs; global

This project aims to establish an advanced, industry-linked pipeline for the development of new drugs against resilient infectious agents (parasites) that cause serious diseases in billions of animals worldwide. The research expects to discover new ways of killing parasites that survive in their host animal, despite being under severe attack by the host immune system. The resultant shift in fundamental understanding will lead to innovative technologies or products to ameliorate the burden of parasites in livestock animals. Expected socioeconomic benefits include commercial products for end-users and lifting Australia’s scientific knowledge base, reputation in biotechnology, livestock production and investment in translational research.

该项目旨在建立一个先进的、与行业相关的管道，用于开发针对全球数十亿动物导致严重疾病的具有弹性的传染性病原体（寄生虫）的新药。这项研究希望发现新的方法，杀死那些在宿主动物体内存活的寄生虫，尽管它们受到宿主免疫系统的严重攻击。由此产生的基本认识的转变将导致创新技术或产品，以减轻牲畜寄生虫的负担。预期的社会经济效益包括为最终用户提供商业产品，提高澳大利亚的科学知识基础，在生物技术、畜牧业生产和转化研究方面的投资方面的声誉。